Symposium:
115. Great Debates in Mycology
Saturday, October 22, 2011: 10:15 AM-11:45 AM
Room: 205ABC

Learning Objectives:

This program is directed to infectious diseases physicians or others involved in management of candidiasis and opportunistic mold infections. It is assumed that audience participants know or are familiar with the basic epidemiology, risk factors, diagnosis and current agents used for treatment these infections. Upon completion of this session, the participant will be able to:

  • evaluate whether available evidence is convincing about the role of catheter removal in clearance of catheter-associated candidiasis
  • determine whether the routine implementation of current in vitro susceptibility methods aid in treatment decisions in candidiasis
  • assess the efficacy of modern antifungals in persistently immunosuppressed patients with opportunistic mycoses.

Target Audience: Scientists, Researchers, Pharmacists, Microbiologists, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Fellows-in-Training, Epidemiologists, Clinicians, Academicians

Tracks: Adult ID

Moderators:  Dimitrios Kontoyiannis, MD, ScD, FACP, FIDSA, MD Anderson Cancer Center, Houston, TX and John E. Edwards, Jr. Jr., MD, FIDSA, Harbor-University of California at Los Angeles Medical Center

CME Credits: Maximum of 1.5 hours of Category 1 credit possible

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-106-L01-P

Disclosures:

D. Kontoyiannis, None

J. E. Edwards, Jr. Jr., NovaDigm Therapeutics Inc.: Consultant and Shareholder, Licensing agreement or royalty
Pfizer: Grant Investigator, Research grant and Salary
Merck: Grant Investigator, Research support and Salary

D. Maki, None

M. Nucci, Pfizer: Board Member, Consultant, Grant Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Educational grant, Research grant and Speaker honorarium
Merck: Board Member, Consultant, Grant Investigator and Scientific Advisor, Consulting fee, Educational grant and Speaker honorarium
Astellas: Board Member, Consultant and Scientific Advisor, Consulting fee and Speaker honorarium

K. A. Marr, Astellas: Consultant and Grant Investigator, Consulting fee and Research grant
Merck: Consultant and Grant Investigator, Consulting fee and Research grant
Pfizer: Consultant and Grant Investigator, Consulting fee and Research grant

J. Baddley, Pfizer: Consultant and Grant Investigator, Consulting fee
Merck: Scientific Advisor, Consulting fee

R. Lewis, Merck & Co: Grant Investigator and Scientific Advisor, Consulting fee and Research grant
Astellas Inc.: Grant Investigator, Research grant
Gilead Inc.: Grant Investigator, Research support

M. Kleinberg, Pfizer: Grant Investigator, Research grant

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.